Phase II Trial of Dexverapamil and Epirubicin in Patients With Non-Responsive Metastatic Breast Cancer

British Journal of Cancer - United Kingdom
doi 10.1038/bjc.1998.192
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

A Phase II Trial of Erlotinib in Combination With Bevacizumab in Patients With Metastatic Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2008English

Phase II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer

The Internet Journal of Oncology
2007English

Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2012English

Multicenter Phase II Study With Weekly Bendamustine and Paclitaxel as First- Or Later-Line Therapy in Patients With Metastatic Breast Cancer: RiTa II Trial

Breast Care
SurgeryOncology
2011English

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients

Oncologist
Cancer ResearchMedicineOncology
2017English

Disease-Free Survival in Patients With Non-Metastatic Breast Cancer

Revista da Associacao Medica Brasileira
Medicine
2016English

Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy

British Journal of Cancer
Cancer ResearchOncology
2018English

Carboplatin in Combination With Epirubicin and Cyclophosphamide in Patients With Advanced Ovarian Cancer: A Phase II Study

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
1995English

N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy

Clinical Breast Cancer
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy